FARXIGA (DAPAGLIFLOZIN)
FARXIGA (DAPAGLIFLOZIN) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: FARXIGA; Generic name: DAPAGLIFLOZIN; Manufacturer: A-S Medication Solutions.
| Brand name | FARXIGA |
|---|---|
| Generic name | DAPAGLIFLOZIN |
| Manufacturer | A-S Medication Solutions |
| Used for | 1 INDICATIONS AND USAGE FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitatio |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Assess volume status and correct volume depletion before initiating. (2.1) eGFR (mL/min/1.73 m 2 ) Recommended Dose eGFR 45 or greater To improve glycemic control, the recommended starting dose is 5 mg orally once daily. Dose can be increased to 10 mg orally once daily for additional glycemic control. For all other indications, the recommended starting dose is 10 mg orally once daily. eGFR 25 to less than 45 10 mg orally once daily eGFR less than 25 Initiation is no |
| Active ingredient(s) | DAPAGLIFLOZIN PROPANEDIOL |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f90c94-71cb-4a1f-81ff-8004b850529b |